{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-24-000033","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.621835+00:00","generated_at":"2026-05-30T03:43:15.836041+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma","bullets":["Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.","WTX-124 monotherapy expansion arms enrolling; initial efficacy data expected H1 2025.","WTX-330 interim data at SITC: 25 patients, 22-fold higher exposure vs rhIL-12, confirmed partial response in melanoma.","New preclinical candidate WTX-921 (IL-10) for inflammatory diseases introduced.","Two WTX-124 patients with confirmed partial responses; one CSCC patient in complete remission >12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-24-000033","json":"https://secwatch.observer/filing/0001785530-24-000033.json","markdown":"https://secwatch.observer/filing/0001785530-24-000033.md","text":"https://secwatch.observer/filing/0001785530-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/0001785530-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/howl-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:43:15.836041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}